Skip to main content

Biolog, Cellomics, GPC Biotech Awarded US Patents


Biolog has received US Patent No. 6,727,076, “Comparative phenotype analysis.” The patent describes an invention related to growing and testing microorganisms in a multitest format utilizing a gel forming matrix for the rapid screening of clinical and environmental cultures, the abstract states. The invention is suited for the characterization of commonly encountered microorganisms (e.g., E. coli, S. aureus, etc.), as well as commercially and industrially important organisms from various and diverse environments (e.g., particularly for the growth and characterization of the actinomycetes and fungi). It is also particularly suited for comparative analysis of phenotypic differences between cell types, including strains of microorganisms that have been designated as the same genus and species, as well as other cell types (e.g., mammalian, insect, and plant cells), the abstract states.

Cellomics has received US Patent No. 6,727,071, “System for cell-based screening.” The patent describes an invention that provides systems, methods, and screens for an optical system analysis of cells, to rapidly determine the distribution, environment, or activity of fluorescently labeled reporter molecules. These activities are aimed at screening large numbers of compounds to find ones that specifically affect particular biological functions, the abstract states. The invention involves providing cells containing fluorescent reporter molecules in an array of locations and scanning numerous cells in each location with a high magnification fluorescence optical system, converting the optical information into digital data, and utilizing the digital data to determine the distribution, environment, or activity of the fluorescently labeled reporter molecules in the cells, the abstract states.

GPC Biotech has received US Patent No. 6,727,082, “Assays and reagents for identifying anti-fungal agents, and uses related thereto.” The patent describes an invention for rapid, reliable and effective assays for screening and identifying pharmaceutically effective compounds that specifically inhibit the biological activity of fungal GTPase proteins, particularly GTPases involved in cell wall integrity, hyphael formation, and/or other cellular functions critical to pathogenesis, the abstract states.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.